|
Research: NU Cancer
| Title:
|
Phase II Trial of Progressive
Resistance Training with Megesterol Acetate for the Treatment of Cancer-related
Weight Loss |
| Funding Source: |
Bristol-Meyers Squibb |
| Start Date:
|
January 1, 1999 |
| Length: |
15 months; 3 Month Set-Up,
12 Months Full Trial |
| Funding:
|
$175,000 (RIC Component:
$46,000) |
| Description: |
Currently, a joint effort between the RIC's Center for Health and
Fitness and the Northwestern Medical Oncology Department is conducting
a study related to the effects of the strength training on the fatigue
levels of terminal cancer patients in conjunction with taking an
appetite stimulant drug, Megesterol Acetate (MA). The strength training
program requires a 3 hour commitment per week for 12 weeks. This
trial will include 15 subjects over a one year period. In addition
to measuring fatigue levels of cancer patients, other evaluations
included in the study are body composition, maximal oxygen consumption
(VO2 max), one repetition maximum, and timed stair climbing.
|
| Title:
|
Phase III Trial of Progressive
Resistance Training Versus Progressive Resistance Training Plus Procrit
for the Treatment of Cancer-related Fatigue |
| Funding Source: |
Ortho Biotech |
| Start Date:
|
January 1, 1999 |
| Length: |
15 Months; 3 Month Set-Up,
12 Months Full Trial |
| Funding:
|
$215,000 (RIC Component:
$43,000) |
| Description: |
RIC's Center for Health and Fitness and the Northwestern
Medical Oncology Department is conducting a second study to test
the effectiveness of the drug, Procrit. This study will investigate
the effects of a 12 week strength and cardiovascular training program
on fatigue levels of cancer patients taking Procrit. Procrit increases
erythropoietin and hemoglobin levels in patients suffering from
anemia exacerbated by chemotherapy and other cancer treatments.
In addition to measuring fatigue levels of 30 cancer subjects, body
composition, maximal oxygen consumption (VO2 max), one repetition
maximum, and timed stair climbing will be considered.
|
|
>
